TCT 576: FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – Final 5 Year Clinical Outcomes

Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:

• Consultant Fee/Honoraria/Speaker’s Bureau - Abbott Vascular; REVA Medical; AstraZenca; CardiacDimensions